Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - CEO Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Financial Officer Conference Call Participants Tim Chiang - Capital One Boris Peaker - Cowen Jacob Hughes - Wells Fargo Securities Operator Good day, and welcome to the Ironwood Pharmaceuticals Q1 2023 Investor Update Conference Call. Today's call is being recorded [O ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34620 IRONWOOD PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 04-34041 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34620 IRONWOOD PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 04-3404176 (St ...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q4 2022 Earnings Conference Call February 16, 2023 8:30 AM ET Company Participants Matt Roache - Director, IR Thomas McCourt - CEO & Director Michael Shetzline - Chief Medical Officer, SVP and Head, Research & Drug Development Sravan Emany - SVP, Principal Financial Officer & CFO Conference Call Participants David Amsellem - Piper Sandler & Co. Daniel Wolle - JPMorgan Chase & Co. Timothy Chiang - Capital One Securities Boris Peaker - Cowen and Company Operator Go ...

Ironwood Q4 and FY 2022 Investor Update February 16, 2023 . Ironwood Safe Harbor Statement This presentation contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability to execute on our vision; our strategy, business, financial position and operations, including with respect to our strategic priorities; the demand, development, commercial availability and commercial potential of linaclotide and the driv ...

Leading in GI through Growth and Innovation J.P. Morgan Healthcare Conference | January 11, 2023 Presented by Tom McCourt CEO, Ironwood Pharmaceuticals, Inc. Nasdaq: IRWD Safe Harbor Statement 2 This presentation contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability to execute on our vision; our strategy, business, financial position and operations, including with respect to our strategic prioritie ...